- Home
- FRTT vs TPST Comparison
FRTT vs TPST Comparison
Compare FRTT & TPST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FRTT | TPST |
|---|---|---|
| Founded | N/A | 2011 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.2M | 15.6M |
| IPO Year | N/A | 2012 |
Fundamental Metrics
Financial Performance| Metric | FRTT | TPST |
|---|---|---|
| Price | $0.97 | $0.93 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $11.00 |
| AVG Volume (30 Days) | ★ 907.5K | 123.2K |
| Earning Date | N/A | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $295,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.72 | $0.87 |
| 52 Week High | $3.92 | $12.22 |
Technical Indicators
Market Signals| Indicator | FRTT | TPST |
|---|---|---|
| Relative Strength Index (RSI) | 33.06 | 34.50 |
| Support Level | $0.94 | N/A |
| Resistance Level | $0.97 | $1.09 |
| Average True Range (ATR) | 0.15 | 0.08 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 25.07 | 35.44 |
Price Performance
Historical ComparisonAbout FRTT Fort Technology Inc. Common Shares
Fort Technology Inc is engaged the identification and evaluation of assets or business with a view to potentially acquire them or an interest therein by an option or any concomitant transaction.
About TPST Tempest Therapeutics Inc.
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets. Company's small-molecule product candidate, amezalpat (previously known as TPST-1120), has completed a Phase 2 study in first-line hepatocellular carcinoma and the second small-molecule product candidate is TPST-1495, plans to initiate a Phase 2 study for in familial adenomatous polyposis.